Answers are grounded in this paper and cite their sources.
Research reveals intestinal bacteria and fungi biotransform baccharin, yielding low-cytotoxic metabolites, highlighting its potential medicinal impact.
Brazilian green propolis has recognised commercial and medicinal value, with baccharin identified as one of its major bioactive compounds, exhibiting cytotoxicity against breast and prostate cancer cell lines. However, the activity of its metabolites remains poorly understood. This study investigated the biotransformation of baccharin by intestinal bacteria and filamentous fungi that mimic human metabolism. Cultures were incubated with 600 µL of baccharin (0.1 mg/mL in ethanol), yielding three metabolites. Escherichia coli, Lactobacillus acidophilus, L. johnsonii, and Saccharomyces boulardii hydrolysed baccharin to drupanin, with up to 79.1% conversion by E. coli after 48 h. Cunninghamella elegans and Aspergillus alliaceus catalysed hydrolysis, hydroxylation, and β-oxidation. Baccharin and its metabolites, evaluated at concentrations ranging from 1.56 to 200 µM, showed low or no cytotoxicity in normal (fibroblasts, MCF-10A, PNT-2) and tumour (MCF-7, MDA-MB-231, DU-145, PC-3) cell lines. Cisplatin and doxorubicin showed IC50 values of 4.6-85.9 µM and <0.78-5.99 µM, respectively, across cell lines.
No takes yet. Share an insight, caveat, or question.
Fonseca et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: